-- ロックス・リソーシズ(ASX:RXL)は、西オーストラリア州にあるユアンミ金鉱山のメインピットの排水作業が完了し、ピットフロアが露出し、過去の傾斜坑が露出したと、木曜日にオーストラリア証券取引所に提出した書類で発表した。 同社は、メイン傾斜坑とポラード傾斜坑に先立つ地下排水作業への移行が進行中であると述べた。 また、ユナイテッド・ノース鉱山では、342メートルの掘削が進み、鉱山開発の記録的な月間進捗を達成したと付け加えた。最初の換気坑の点火に成功し、予想通り最初の開発レベルで鉱化帯が確認された。 さらに、選鉱プラントの土木工事が進行中であり、メインピット発電所は試運転の準備が整っていると述べた。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.